GILEAD SCIENCES, INC.(GILD)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
GILEAD SCIENCES, INC. (GILD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GILD at 57.4/100 on a 32-signal composite quality model, placing it at rank #1,095 of 2,961 stocks — the top half of the AI-ranked universe. GILD scores in the top quartile across revenue scale (95.1), earnings quality (93.0), free cash flow (92.1). Areas of concern include profitability (17.8) and balance sheet strength (21.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GILEAD SCIENCES, INC. reports quarterly revenue of $7.8B, net income of $-10.5B, free cash flow of $3.4B. Top institutional holders of GILD by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. GILD trades on the Nasdaq exchange and files with the SEC under CIK 882095. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GILD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GILEAD SCIENCES, INC. directly from SEC EDGAR.
AI Quality Score
57.4/100
AI Rank
#1,095
Revenue
$7.8B
Net Income
$-10.5B
Free Cash Flow
$3.4B
GILD key financials by period
GILEAD SCIENCES, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$29.4B
$8.5B
34.0%
FY 2024
10-K
$28.8B
$480.0M
5.8%
FY 2023
10-K
$27.1B
$5.7B
28.1%
FY 2022
10-K
$27.3B
$4.6B
26.9%
FY 2021
10-K
$27.3B
$6.2B
36.3%
FY 2020
10-K
$24.7B
$123.0M
16.5%
Institutions holding GILD
Institutional investors reporting a position in GILEAD SCIENCES, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue rose 10% to $7.8B, but $11.2B of acquired IPR&D charges from the Arcellx, Tubulis and Ouro deals plus a $1.75B impairment produced a $10.5B net loss.
Biggest Revenue Drivers
HIV$5,693M+12% YoY
Primarily due to higher average realized price and demand
Liver Disease$877M+10% YoY
Higher demand for Livdelzi, hepatitis B products and Hepcludex, offset by lower HCV sales
Biggest Revenue Drivers
Total revenue: $7,803M+10% YoY
HIV$5,693M+12% YoY
Primarily due to higher average realized price and demand
Within HIV
Biktarvy$3,772M+7% YoY
Higher average realized price, favorable inventory dynamics and patients switching from Genvoya
Liver Disease$877M+10% YoY
Higher demand for Livdelzi, hepatitis B products and Hepcludex, offset by lower HCV sales
Oncology$873M+3% YoY
Trodelvy growth offset by Cell Therapy decline on competitive headwinds
Within Oncology
Trodelvy$457M+26% YoY
Primarily due to higher demand
Largest Expense Items
Acquired in-process research and development$11,183Mvs $61M a year ago
$7.0B Arcellx, $3.1B Tubulis and $1.0B Ouro Medicines net of Lakefront's $860M share
Selling, general and administrative$1,921M+41% YoY
Higher HIV promotional spend and integration costs, including $332M of acquisition-related stock-based compensation
Research and development$1,764M+18% YoY
Integration expenses including $229M of stock-based compensation from the acquisitions; clinical study costs fell 3%
In-process research and development impairments$1,750Mvs $190M a year ago
Full write-off of the NSCLC IPR&D asset after discontinuing the Phase 3 EVOKE-03 Trodelvy study
Margins: Product gross margin was 79.3%, described as relatively flat versus 78.7% a year ago (+58 bps). Cost of goods sold rose 5% to $1,579M.
Watch Items from the Filing
Acquisitions consumed liquidity: cash fell to $3.2B from $7.6B, all marketable debt securities were sold, and total debt rose to $26.2B.
HHS selected Biktarvy — a $3.8B quarterly product — for Medicare Maximum Fair Price determination effective 2028.
Approximately 60% of accounts receivable relates to three wholesalers: Cardinal Health, Cencora and McKesson.
Cell Therapy sales fell 14% to $417M on lower demand reflecting ongoing competitive headwinds; Veklury fell 81% to $23M.
Product liability suits involve approximately 23,000 active plaintiffs; California Supreme Court ruled in Gilead's favor in August 2026, federal bellwether trial set for March 2027.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
